Breaking News

BioNTech Acquires Novartis Mfg. Site in Singapore for mRNA Production

Establishes regional manufacturing capacities to support pipeline of mRNA-based vaccines and therapeutics across Asia Pacific region.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioNTech’s Singapore affiliate BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. entered an agreement with Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. to acquire one of its GMP-certified manufacturing facilities. The acquisition is part of BioNTech’s expansion strategy to strengthen its global footprint in Asia. The facility will serve as BioNTech’s Regional Headquarters and become its first mRNA manufacturing facility in Singapore.   The Singapore mRNA manufacturing facility will ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters